Monitoring of QTc interval in patients with COVID-19. First experience with a portable ECG-recording device

Abellas-Sequeiros, Maria; Granero, Cristina Lozano; García-Sebastián, Cristina; Franco-Díez, Eduardo; Hernández‐Madrid, Antonio; Moreno, Javier; Masjuan-Vallejo, Jaime; Sanmartín-Fernández, Marcelo; Zamorano-Gómez, José Luis

doi:10.5603/cj.a2021.0033

Cited by 4 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acceptable QT/QTc interval measurements were performed. Abellas-Sequeiros et al ( 22 ) published a research letter about QT interval monitoring in patients with COVID-19 with KardiaMobile 6L. Seventy patients were enrolled, and tracings obtained with KardiaMobile 6L were of sufficient quality to provide an accurate QT interval measurement in 69 of them (98.6%).…”

Section: Resultsmentioning

confidence: 99%

Smart devices to measure and monitor QT intervals

Hoek,

Brouwer,

Voors

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Careful observation of the QT interval is important to monitor patients with long QT syndrome and during treatment with potentially QT-prolonging medication. It is also crucial in the development of novel drugs, in particular in case of a potential side effect of QT prolongation and in patients with increased risk of QT prolongation. The 12-lead electrocardiogram (ECG) is the gold standard to evaluate cardiac conduction and repolarization times. Smartwatches and smart devices offer possibilities for ambulatory ECG recording and therefore measuring and monitoring the QT interval. We performed a systematic review of studies on smartwatches and smart devices for QTc analysis. We reviewed PubMed for smartwatches and smart devices that can measure and monitor the QT interval. A total of 31 studies were included. The most frequent devices were (1) KardiaMobile 6L, a Food and Drug Administration-approved device for QTc analyses that provides a 6-lead ECG, (2) an Apple Watch, a smartwatch with an integrated ECG tool that allows recording of a single-lead ECG, and (3) the Withings Move ECG ScanWatch, an analog watch with a built-in single-lead ECG. The KardiaMobile 6L device and the Apple Watch provide accurate measurements of the QT interval, although the Apple Watch is studied in standard and non-standard positions, and the accuracy of QT measurements increased when the smartwatch was moved to alternative positions. Most studies were performed on patients, and limited results were available from healthy volunteers.

show abstract

Section: Resultsmentioning

confidence: 99%

Smart devices to measure and monitor QT intervals

Hoek,

Brouwer,

Voors

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…However, the implementation of manual measurement of repolarization ECG markers in the clinical setting is prone to variability by intra- or inter-observer bias. In addition, differences in determining QTc interval measurement exist in various published studies, such as the heart-rate correction methods by Bezett or Framingham [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Is T-Wave Alternans a Repolarization Abnormality Marker in COVID-19? An Investigation on the Potentialities of Portable Electrocardiogram Device

Tondas¹,

Munawar

Marcantoni

et al. 2023

Cardiol Res

View full text Add to dashboard Cite

Background: Cardiac arrhythmias are significantly associated with poor outcomes in coronavirus disease 2019 patients. Microvolt T-wave alternans (TWA) can be automatically quantified and has been recognized as a representation of repolarization heterogeneity and linked to arrhythmogenesis in various cardiovascular diseases. This study aimed to explore the correlation between microvolt TWA and COVID-19 pathology.Methods: Patients suspected of COVID-19 in Mohammad Hoesin General Hospital were consecutively evaluated using Alivecor ® Kardiamobile 6L™ portable electrocardiogram (ECG) device. Severe COVID-19 patients or those who are unable to cooperate in active ECG self-recording were excluded from the study. TWA was detected and its amplitude was quantified using the novel enhanced adaptive match filter (EAMF) method.Results: A total of 175 patients, 114 COVID-19 patients (polymerase chain reaction (PCR)-positive group), and 61 non-COVID-19 pa-tients (PCR-negative group) were enrolled in the study. PCR-positive group was subdivided according to the severity of COVID-19 pathology into mild and moderate severity subgroups. Baseline TWA levels were similar between both groups during admission (42.47 ± 26.52 µV vs. 44.72 ± 38.21 µV), but higher TWA levels were observed during discharge in the PCR-positive compared to the PCR-negative group (53.45 ± 34.42 µV vs. 25.15 ± 17.64 µV, P = 0.03). The correlation between PCR-positive result in COVID-19 and TWA value was significant, after adjustment of other confounding variables (R 2 = 0.081, P = 0.030). There was no significant difference in TWA levels between mild and moderate severity subgroups in patients with COVID-19, both during admission (44.29 ± 27.14 µV vs. 36.75 ± 24.46 µV, P = 0.34) and discharge (49.47 ± 33.62 µV vs. 61.09 ± 35.99 µV, P = 0.33). Conclusions:Higher TWA values can be observed on follow-up ECG obtained during discharge in the PCR-positive COVID-19 patients.

show abstract

“…In the current issue of the journal, Abellas--Sequeiros et al [2] report an experience using a hand-held ECG-recording device to measure the QTc interval in patients with COVID-19. The authors used the KardiaMobile6L ® 6-lead ECG to make recordings at varying frequencies in patients who were taking azithromycin, hydroxychloroquine, lopinavir/ritonavir, or combinations of these drugs.…”

mentioning

confidence: 99%